Cummings et al. [26] focus on the fact that GLP-1 analogue administered once daily in patients with impaired glucose tolerance or with diabetes de novo decreases postprandial triglyceride, apolipoproteins: B-48, C III, and also cholesterol and triglyceride remnants which results in significant reduction of cardiovascular complication risk factors. This evidence concerns the gene GLP1R and diabetes mellitus.